Form 4: AbCellera Director Michael Hayden Receives Option Grant

Director Michael R. Hayden was granted 111,701 stock options in AbCellera Biologics Inc. as part of standard compensation.

Summary

• Director Michael R. Hayden received a grant of 111,701 stock options on June 11, 2026.
• The options have an exercise price of $5.27 per share.
• The options are set to vest at the 2027 Annual General Meeting, contingent upon continued service.
• The expiration date for these options is June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is subject to the director's continuous service to the issuer.

Future Outlook

The options vest at the 2027 Annual General Meeting, indicating a long-term retention incentive for the director.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure leadership alignment with company performance and long-term strategic goals.

Comparison to Industry Standards

• The use of time-based vesting for director compensation is consistent with standard corporate governance practices for NASDAQ-listed biotech firms.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options at the 2027 Annual General Meeting.

Key Dates

Keywords

AbCellera, ABCL, Form 4, Insider Trading, Stock Options, Biotech